For example, Lin et al. developed a molybdenum SAzymes (Mo SAs) capable of exerting potent therapeutic effects on immune checkpoint blockade (ICB)-resistant tumors [46], Mo SAs can remodel the tumor immune microenvironment by inducing tumor immunogenic cell death, alleviating tumor hypoxia, and modulating tumor chemokine expression, which further enhances the anti-tumor efficacy with anti-PD-L1 therapy and highlights its potential for treating ICB-resistant tumors. Here, CD274 is linked to neoplasm.